IMCR logo

Immunocore Holdings plc (IMCR)

$28.88

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on IMCR

Market cap

$1.49B

EPS

-0.72

P/E ratio

--

Price to sales

10.37

Dividend yield

--

Beta

0.820845

Price on IMCR

Previous close

$29.94

Today's open

$30.04

Day's range

$28.77 - $30.48

52 week range

$27.50 - $40.71

Profile about IMCR

CEO

Bahija Jallal

Employees

524

Headquarters

Abingdon, Oxfordshire

Exchange

Nasdaq Global Select

Shares outstanding

51681376

Issue type

American Depository Receipt

IMCR industries and sectors

Healthcare

Biotechnology & Life Sciences

News on IMCR

Immunocore Holdings plc (IMCR) Presents at UBS Global Biopharma Conference 2026 Transcript

Immunocore Holdings plc (IMCR) Presents at UBS Global Biopharma Conference 2026 Transcript

news source

Seeking Alpha • 11 hours ago

news preview

Immunocore to present at upcoming investor conferences

(OXFORDSHIRE, England & RADNOR, PA & GAITHERSBURG, MD, US, 09 November 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced management will participate at the following conferences in November.

news source

GlobeNewsWire • Nov 9, 2026

news preview

Immunocore reports third quarter financial results and provides a business update

KIMMTRAK ® (tebentafusp-tebn) net revenues of $102.2 million in Q3 2026 and net revenues of $324.8 million for the first nine months of 2026, representing 10% year-over-year growth year to date

news source

GlobeNewsWire • Nov 6, 2026

news preview

Immunocore presents promising data from Phase 1/2 trial cohort evaluating brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma

In 17 first-line patients treated with the combination, the estimated two-year overall survival (OS) rate was 70% - Median OS was not reached at a median follow-up of 29 months and 10 patients remained on study

news source

GlobeNewsWire • Nov 6, 2026

news preview

Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting

Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK ® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting

news source

GlobeNewsWire • Oct 29, 2026

news preview

Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes

Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes The Phase 1 trial will assess the safety and clinical activity of IMC-S118AI in HLA-A*02:01-positive patients with type 1 diabetes Preclinical data supporting unique mechanism of action recently published in Science Advances (OXFORDSHIRE, England & RADNOR, PA & GAITHERSBURG, MD, US, 15 October 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that the first patient with type 1 diabetes (T1D) has been dosed in the Phase 1 trial (NCT07493122) of IMC-S118AI1. IMC-S118AI, the Company's first candidate for autoimmune diseases, is a novel bispecific molecule designed to down-modulate the immune system in a tissue-specific manner to protect beta cells under T cell attack in T1D.

news source

GlobeNewsWire • Oct 15, 2026

news preview

Immunocore Holdings plc (IMCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Immunocore Holdings plc (IMCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

news source

Seeking Alpha • Sep 15, 2026

news preview

Immunocore Hits Enrollment Target in Kimmtrak Label Expansion Study

IMCR achieves target enrollment in the phase III TEBE-AM study investigating Kimmtrak in previously treated patients with advanced melanoma.

news source

Zacks Investment Research • Sep 15, 2026

news preview

Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma

Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK ® (tebentafusp) in previously treated advanced melanoma Topline overall survival data expected as early as end of 2026 (OXFORDSHIRE, England & CONSHOHOCKEN, PA & ROCKVILLE, MD, US, 14 September 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced the achievement of target patient enrollment (540 patients) in the TEBE-AM clinical trial (NCT05549297). TEBE-AM is a global, randomized, registrational Phase 3 clinical trial evaluating KIMMTRAK (tebentafusp) as monotherapy and in combination with pembrolizumab, versus Investigator's Choice, for the treatment of HLA-A*02:01-positive patients with advanced melanoma whose disease has progressed following prior therapy.

news source

GlobeNewsWire • Sep 14, 2026

news preview

Will Kimmtrak Continue to Aid IMCR's Growth Through the Rest of 2026?

Strong demand for Kimmtrak is fueling Immunocore's growth, while potential label expansion and late-2026 data could add further upside.

news source

Zacks Investment Research • Aug 25, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Immunocore Holdings plc

Open an M1 investment account to buy and sell Immunocore Holdings plc commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in IMCR on M1